Quest Diagnostics Names Adrienne Brott Senior Vice President and Chief Quality and Regulatory Affairs Officer
Quest Diagnostics (NYSE: DGX) has appointed Adrienne L. Brott as senior vice president and chief quality and regulatory affairs officer, effective December 2024. Reporting to CEO Jim Davis, Brott will lead the company's quality and regulatory strategy, focusing on enhancing quality adherence and compliance with global regulations for laboratory diagnostic services.
Brott joins Quest with extensive experience in healthcare quality and regulatory affairs, previously serving as senior vice president of quality and regulatory at Getinge's acute care therapies division. Her prior roles include leadership positions at Becton Dickinson, where she managed quality across 28 manufacturing sites and led a program to harmonize 120 quality management systems. She also held positions at Johnson & Johnson and Abbott Laboratories.
The new executive is co-chair of the Advancing Quality Excellence Collaborative Community Steering Committee of the Medical Device Innovation Consortium, collaborating with stakeholders including the FDA to improve medical device quality and patient safety.
Quest Diagnostics (NYSE: DGX) ha nominato Adrienne L. Brott come vicepresidente senior e direttore delle qualità e dei rapporti normativi, con effetto da dicembre 2024. Riportando direttamente al CEO Jim Davis, Brott guiderà la strategia di qualità e normativa dell'azienda, concentrandosi sul miglioramento dell'aderenza alla qualità e della conformità alle normative globali per i servizi diagnostici di laboratorio.
Brott si unisce a Quest con una vasta esperienza nel settore della qualità e dei rapporti normativi in sanità, avendo precedentemente ricoperto il ruolo di vicepresidente senior della qualità e dei rapporti normativi nella divisione delle terapie acute di Getinge. Le sue precedenti esperienze comprendono posizioni di leadership presso Becton Dickinson, dove ha gestito la qualità in 28 sedi di produzione e ha guidato un programma per armonizzare 120 sistemi di gestione della qualità. Ha anche ricoperto ruoli presso Johnson & Johnson e Abbott Laboratories.
La nuova dirigente è co-presidente del Comitato Direttivo della Advancing Quality Excellence Collaborative Community del Medical Device Innovation Consortium, collaborando con le parti interessate, inclusa la FDA, per migliorare la qualità dei dispositivi medici e la sicurezza dei pazienti.
Quest Diagnostics (NYSE: DGX) ha nombrado a Adrienne L. Brott como vicepresidenta senior y directora de calidad y asuntos regulatorios, con efecto a partir de diciembre de 2024. Reportando al CEO Jim Davis, Brott liderará la estrategia de calidad y regulación de la empresa, enfocándose en mejorar la adherencia a la calidad y el cumplimiento de las regulaciones globales para los servicios de diagnóstico de laboratorio.
Brott se une a Quest con una amplia experiencia en calidad y asuntos regulatorios en el ámbito de la salud, habiendo desempeñado previamente el cargo de vicepresidenta senior de calidad y regulación en la división de terapias agudas de Getinge. Sus experiencias anteriores incluyen puestos de liderazgo en Becton Dickinson, donde gestionó la calidad en 28 sitios de fabricación y lideró un programa para armonizar 120 sistemas de gestión de calidad. También ha ocupado puestos en Johnson & Johnson y Abbott Laboratories.
La nueva ejecutiva es copresidenta del Comité Directivo de la Advancing Quality Excellence Collaborative Community del Medical Device Innovation Consortium, colaborando con partes interesadas, incluida la FDA, para mejorar la calidad de los dispositivos médicos y la seguridad de los pacientes.
Quest Diagnostics (NYSE: DGX)가 Adrienne L. Brott를 선임 부사장 겸 품질 및 규제 업무 책임자로 임명하였으며, 이는 2024년 12월부터 효력이 발생합니다. Brott는 CEO인 Jim Davis에게 보고하며, 회사의 품질 및 규제 전략을 이끌어가며 실험실 진단 서비스의 품질 준수와 글로벌 규제에 대한 준수를 향상시키는 데 주력할 것입니다.
Brott는 Getinge의 응급 치료 섹터에서 품질 및 규제 책임자 부사장직을 수행한 광범위한 의료 품질 및 규제 업무 경험을 바탕으로 Quest에 합류합니다. 그녀의 이전 경력에는 Becton Dickinson에서 품질을 28개 제조 시설에서 관리하고 120개의 품질 관리 시스템을 통합하는 프로그램을 주도한 리더십 역할이 포함됩니다. 또한 Johnson & Johnson 및 Abbott Laboratories에서 근무한 경험이 있습니다.
신임 임원은 의료 기기 혁신 컨소시엄의 품질 향상 협력 커뮤니티 운영 위원회의 공동 의장을 맡고 있으며, FDA를 포함한 이해 관계자들과 협력하여 의료 기기 품질 및 환자 안전을 개선하고 있습니다.
Quest Diagnostics (NYSE: DGX) a nommé Adrienne L. Brott au poste de vice-présidente senior et responsable de la qualité et des affaires réglementaires, à compter de décembre 2024. Relevant du PDG Jim Davis, Brott dirigera la stratégie de qualité et de réglementation de l'entreprise, en se concentrant sur l'amélioration de l'adhérence à la qualité et de la conformité aux réglementations mondiales pour les services de diagnostic en laboratoire.
Brott rejoint Quest avec une vaste expérience dans le domaine de la qualité et des affaires réglementaires en santé, ayant précédemment occupé le poste de vice-présidente senior de la qualité et de la réglementation dans la division des thérapies aiguës de Getinge. Ses expériences antérieures incluent des postes de direction chez Becton Dickinson, où elle a géré la qualité à travers 28 sites de fabrication et a mené un programme d'harmonisation de 120 systèmes de gestion de la qualité. Elle a également occupé des postes chez Johnson & Johnson et Abbott Laboratories.
La nouvelle dirigeante est co-présidente du Comité de Pilotage de l'Advancing Quality Excellence Collaborative Community du Medical Device Innovation Consortium, en collaborant avec des parties prenantes, y compris la FDA, pour améliorer la qualité des dispositifs médicaux et la sécurité des patients.
Quest Diagnostics (NYSE: DGX) hat Adrienne L. Brott zur Senior Vice President und Chief Quality and Regulatory Affairs Officer ernannt, wirksam ab Dezember 2024. Sie wird an CEO Jim Davis berichten und die Qualitäts- und Regulierungsstrategie des Unternehmens leiten, wobei der Fokus auf der Verbesserung der Qualitätseinhaltung und der Einhaltung globaler Vorschriften für diagnostische Laborleistungen liegt.
Brott kommt mit umfangreicher Erfahrung im Bereich Gesundheitsqualität und regulatorische Angelegenheiten zu Quest. Zuvor war sie Senior Vice President für Qualität und Regulierung in der Akuttherapiesparte von Getinge. Zu ihren bisherigen Positionen gehören Führungsrollen bei Becton Dickinson, wo sie die Qualität an 28 Produktionsstandorten verwaltete und ein Programm zur Harmonisierung von 120 Qualitätsmanagementsystemen leitete. Zudem hatte sie Positionen bei Johnson & Johnson und Abbott Laboratories inne.
Die neue Führungskraft ist Co-Vorsitzende des Steering Committee der Advancing Quality Excellence Collaborative Community des Medical Device Innovation Consortium und arbeitet mit Stakeholdern, einschließlich der FDA, zusammen, um die Qualität von Medizinprodukten und die Sicherheit der Patienten zu verbessern.
- Strategic appointment strengthens regulatory compliance capabilities
- New executive brings extensive experience from major healthcare companies
- Addition of seasoned leader to executive team enhances quality management expertise
- None.
Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team
Ms. Brott is responsible for leading the company's quality and regulatory strategy to enhance quality adherence and control as well as compliance with
"Adrienne is a highly effective leader with an impressive record of strengthening and streamlining quality and regulatory processes for complex healthcare companies," Mr. Davis said. "Under her leadership, Quest will be well positioned to navigate an evolving regulatory landscape and fulfill our high standards for quality."
Prior to joining Quest, Ms. Brott was senior vice president, quality and regulatory for the acute care therapies division of Getinge, a global medical technology company. Before that, she held various leadership roles at Becton Dickinson (BD), a leading global medical technology company. This includes senior vice president, quality management--interventional segment, quality systems and regions, where she led all aspects of quality across 28 manufacturing sites worldwide and led a multi-year program to simplify and harmonize 120 quality management systems. She held other roles of increasing responsibility in quality systems and post-market quality and regulatory compliance and quality operations and end-to-end integrated supply chain operations for medical devices and other areas for Johnson & Johnson and Abbott Laboratories.
Ms. Brott is a co-chair of the Advancing Quality Excellence Collaborative Community (AQEcc) Steering Committee of the Medical Device Innovation Consortium (MDIC), an initiative shared by medical device stakeholders, including the FDA, to enhance medical device quality and patient safety.
Ms. Brott earned a Master of Business Administration (M.B.A.) degree from the Lake Forest Graduate School of Management and a bachelor's degree with a double major in biology and environmental studies from
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-names-adrienne-brott-senior-vice-president-and-chief-quality-and-regulatory-affairs-officer-302345585.html
SOURCE Quest Diagnostics
FAQ
When did Adrienne Brott join Quest Diagnostics (DGX) as chief quality officer?
What is Adrienne Brott's role at Quest Diagnostics (DGX)?
What was Adrienne Brott's previous position before joining Quest Diagnostics (DGX)?
What are Adrienne Brott's key achievements at Becton Dickinson before joining DGX?
